Physician profile
Vincent Chan
NPI 1649782590
$2,058.79
in general payments reported to CMS, 2019-2025
16 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $130 · 2022: $125 · 2023: $238 · 2024: $595 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.15 | 2021-2025 | Fasenra, Airsupra |
| Insmed, INC. | $279.29 | 2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $210.01 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $187.95 | 2023-2025 | |
| Glaxosmithkline, LLC. | $173.54 | 2023-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $150.56 | 2023-2025 | Zerbaxa, Recarbrio |
| Janssen Pharmaceuticals, INC | $125.00 | 2022 | |
| Pfizer INC. | $115.38 | 2019 | |
| Genentech USA, INC. | $110.17 | 2023-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $90.70 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.87 | 2024-2025 | Ofev |
| Amgen INC. | $68.16 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $49.47 | 2025 | Ohtuvayre |
| Philips North America LLC | $45.87 | 2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2024 | Aralast |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $21.89 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.